Country policymakers, donors, and global health organisations, on Monday, on the sidelines of the Generation Equality Forum – a major global inflection point for gender equality – announced a new initiative to accelerate progress on ensuring access to a comprehensive range of sexual and reproductive health (SRH) products.
Despite significant improvements in the last decade, essential SRH health tools remain out of reach for millions of people worldwide, and health system disruptions from the COVID-19 pandemic threaten to widen the gap.
Shaping Equitable Market Access for Reproductive Health, known as SEMA Reproductive Health – will support countries in overcoming some of the biggest barriers in SRH markets to ensure people everywhere can access the products they want and need to control their health and futures. Donors have committed over USD$50 million to SEMA to date, and the partnership aims to raise at least $50 million for core funding over the next five years.
Director and Head of the Reproductive Health Division at Nigeria’s Federal Ministry of Health, Dr. Kayode Afolabi, said: “When women and girls lack access to SRH products – like contraceptives and medicines to manage pregnancy-related complications – whole communities suffer.
“Healthy SRH markets are essential to strong health systems, and we look forward to collaborating with SEMA Reproductive Health to make markets work better for women and girls.”
SEMA will bring together a diverse set of partners to:
•Proactively monitor SRH market health by aggregating datasets and building a holistic unified view of user demand and current market supply across regions and sectors.
•Identify market barriers across geographies and co-design strategic solutions, tapping the unique strengths of existing networks and organisations in-country and globally.
•Support countries and global partners to finance and implement interventions by helping governments mobilize domestic funding, crowding in new players, and coordinating global investments to maximize impact.
SRH products are instrumental to women’s and girls’ health and wellbeing, helping to avert unintended pregnancies and unsafe abortions and prevent maternal deaths.
“Comprehensive SRH choices that match people’s preferences increase the likelihood that women and girls finish school and achieve their ambitions,” said Kate Hampton, CEO of the Children’s Investment Fund Foundation. “If we’re going to achieve a gender equal world, we need access to those choices to be based on their needs, rather than on what donors decide. I’m delighted for the launch of SEMA Reproductive Health as it’s an opportunity to rethink how we solve SRH market challenges, support countries and communities to take ownership, and enable women to make decisions about their own health and futures.”
Over the past decade, global institutions have worked alongside countries and local organisations to enable over 60 million additional women and girls in 69 low- and middle-income countries to use modern contraception. Many countries have also increased the diversity of contraceptive options available, such as implants and self-injectable contraception, helping more women and girls find methods that work for them.
“It is necessary to guarantee for all of the world’s women and girls the respect for their right to freely control their own bodies, which includes improved access to modern contraceptives,” said Jean-Yves Le Drian, French Minister of Europe and Foreign Affairs. “Echoing the United Nations 2030 Agenda and the human development goals we aim to achieve, this is an indispensable condition for true gender equality between women and men, and one that France has placed at the heart of its feminist diplomacy.”
Unfortunately, persistent weaknesses in current markets still prevent many women and girls from being able to access high-quality, affordable, and diverse SRH options that fit their preferences. Systems and data for SRH products are highly fragmented with limited coordination across public and private healthcare delivery channels.
This can lead to inefficiencies and unpredictability in the availability of supplies, and prices that keep products out of reach for many. Country and global partners also do not have adequate information to fully understand people’s preferences and choices around SRH products – critical insights for providing the right amounts of the right products to best serve populations.
Strategies to solve access challenges often happen on a product-by-product basis, with unintended consequences for the broader market. Additionally, these efforts have heavily relied on a few global institutions instead of being driven by country governments themselves, limiting how well or sustainably interventions actually address communities’ needs.
Tackling these challenges could have dramatic impact. 218 million women in low- and middle-income countries who want to avoid or delay pregnancy are not using modern contraceptives and approximately 810 women die every day from causes related to pregnancy, unsafe abortion, and childbirth. Currently, from development to launch, new contraceptives often take years longer to be introduced to low- and middle-income country markets than other global health products.